Evotec Buys Zebrafish Screening Business of Summit | GenomeWeb

NEW YORK (GenomeWeb News) – German firm Evotec said today that it will buy the zebrafish screening operations of UK company Summit for around £500,000 ($754,000).

The small molecule drug developer plans to use the new Summit operations in Abingdon, UK, and in Singapore, to prioritize promising compounds early in the drug discovery process.

Summit had agreements with a number of drug makers, including a three-year alliance with Johnson & Johnson, and collaborations with Bayer-Schering, Merck KGaA, Roche, and others.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.

Research funding in Canada is to remain mostly the same, ScienceInsider reports.

In Science this week: random DNA replication errors play role in cancer, and more.

The Bill and Melinda Gates Foundation embarks on an open-access publishing path.